2-(4-苯基-1-哌啶基)乙胺 | 41914-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(4-苯基-1-哌啶基)乙胺
• 英文名称: 2-(4-phenylpiperidin-1-yl)ethanamine
• 英文别名: 2-(4-phenylpiperidino)ethylamine；2-(4-phenyl-piperidin-1-yl)-ethylamine；1-(2-aminoethyl)-4-phenylpiperidine；1-<2-Amino-aethyl>-4-phenyl-piperidin
• CAS: 41914-43-6
• 化学式: C₁₃H₂₀N₂
• mdl: MFCD09055208
• 分子量: 204.315
• InChiKey: BFKSDLKIKGGPJK-UHFFFAOYSA-N

物化性质

• 沸点：
  321.0±35.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(4-苯基-1-哌啶基)乙胺 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-((3-isopropylisoxazol-5-yl)methyl)-2-(4-phenylpiperidin-1-yl)ethanamine
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4-phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

  摘要：

  New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Ca(v)3.1 (alpha(1G)) and Ca(v)3.2 (alpha(1H)) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of alpha(1G) and am subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.12.056
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 正丁基锂 、 palladium on activated charcoal 、 氢气 、 sodium carbonate 、 一水合肼 、 三氟乙酸 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 43.5h， 生成 2-(4-苯基-1-哌啶基)乙胺
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4-phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

  摘要：

  New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Ca(v)3.1 (alpha(1G)) and Ca(v)3.2 (alpha(1H)) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of alpha(1G) and am subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.12.056

文献信息

• Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A_2AReceptor
  作者：Dong Guo、Lizi Xia、Jacobus P. D. van Veldhoven、Marc Hazeu、Tamara Mocking、Johannes Brussee、Adriaan P. IJzerman、Laura H. Heitman

  DOI：10.1002/cmdc.201300474

  日期：2014.4

  compound’s binding kinetics have been largely ignored, the importance of which is now being increasingly recognized. In the present study, we performed an extensive structure–kinetics relationship (SKR) study in addition to a traditional SAR analysis at the adenosine A2A receptor (A2AR). The ensemble of 24 A2AR compounds, all triazolotriazine derivatives resembling the prototypic antagonist ZM241385 (4‐(

  经典药物的设计和开发主要依赖于亲和力或效价驱动的结构-活性关系（SAR）。迄今为止，给定化合物的结合动力学已被很大程度上忽略，其重要性现在越来越被人们所认识。在本研究中，除了对腺苷A 2A受体（A 2A R）进行传统的SAR分析外，我们还进行了广泛的结构动力学关系（SKR）研究。由24 A 2A R化合物组成的化合物，所有三唑三嗪衍生物均类似于原型拮抗剂ZM241385（4-（2-（（7-氨基-2-（呋喃-2-基）-[1,2,4]三唑[1， 5一] [1,3,5] triazin-5-基）氨基）乙基）苯酚）在亲和力上仅显示微小差异，尽管它们与受体的解离速率差异很大。我们相信，像我们对A 2A R所做的那样，SKR和SAR分析的这种结合对于G蛋白偶联受体的超家族将具有普遍的重要性，因为它可以作为调整配体之间相互作用的新策略和受体。
• 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130085128A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。
• Carboxamide spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20070111982A1

  公开（公告）日：2007-05-17

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及一种对CGRP受体具有拮抗作用的化合物，可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Carboxamide Spirolactam Cgrp Receptor Antagonists
  申请人：Williams M. Theresa

  公开号：US20070293470A1

  公开（公告）日：2007-12-20

  The present invention is directed to compounds of Formula I: I (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中变量A1、A2、B、J、K、m、n、R4、R5a、R5b和R5c如本文所定义），用作CGRP受体的拮抗剂，并用于治疗或预防涉及CGRP的疾病，例如头痛、偏头痛和群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的使用。
• Dihydrouracile, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0000220A1

  公开（公告）日：1979-01-10

  Neue Hexahydropyrimidine der Formel (I) (siehe Formelblatt) worin bedeuten: R1 Wasserstoff, Alkyl mit bis zu 2 C-Atomen, Phenyl oder Tolyl, R2 bis R5 Wasserstoff oder Alkyl mit bis zu 2 C-Atomen, wobei R2 bis R3 gleich oder verschieden sind, R6 Wasserstoff, einen anellierten Benzolring oder 1 bis 3 gleiche oder verschiedene Substituenten der Gruppe Alkoxy mit 1 bis 3 C-Atomen, Halogen, Nitro, Hydroxy oder Alkyl mit 1 bis 4 C-Atomen, das unsubstituiert oder mit mindestens einem Halogen-atom substituiert ist, eine Einfachbindung oder die Gruppe C6H5,-CH Q eine Einfachbindung oder Alkylen mit n = 2 bis 6 C-Atomen, wobei mindestens 2 C-Atome zwischen den beiden Stickstoffatomen stehen, oder ein solches Alkylen, das mit höchstens (n-2) Hydroxylgruppen substituiert ist, wobei die OH-Gruppe in anderer als geminaler Stellung zum Stickstoff stehen. Sauerstoff oder Schweferl u Ztickstoff oder die Grupper H einschließlich der Säureadditionssalze der Verbindungen der Formel (1), Verfahren zu deren Herstellung sowie Arzneimittel enthaltend diese Verbindungen.

  式(I)的新六氢嘧啶（见式表），其中： R1 是氢、最多 2 个碳原子的烷基、苯基或甲苯基、 R2 至 R5 是氢或最多有 2 个碳原子的烷基、 其中 R2 至 R3 相同或不同、 R6 是氢、熔合苯环或 1 至 3 个相同或不同的取代基，这些取代基来自具有 1 至 3 个碳原子的烷氧基、卤素、硝基、羟基或具有 1 至 4 个碳原子的烷基（未被取代或至少被一个卤素原子取代）组成的组、 单键或基团 C6H5,-CH Q 是单键或具有 n = 2 至 6 个碳原子的亚烷基，在两个氮原子之间至少有 2 个碳原子，或者是最多被 (n-2) 个羟基取代的亚烷基，羟基的位置不在基团上 的位置。 氧或硫 氮或 H 包括式(1)化合物的酸加成盐、其制备方法和含有这些化合物的药物。